Allogene Therapeutics, Inc. (ALLO) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Allogene Therapeutics, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.48HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
MNPR
Monopar Therapeutics Inc.
$78.23HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — ALLO vs MNPR
growth of $100 · dividends reinvested · last 7yALLO -94.5% (-33.9%/yr)MNPR -40.9% (-7.2%/yr)MNPR compounded faster over this window
Log scale — wide-divergence pair
ALLO MNPR
ALLO vs MNPR: by the numbers
- •MNPR is the larger company ($524M vs $511M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -3566.68% net margin).
Metrics side by side
Valuation
| Metric | ALLO | MNPR |
|---|---|---|
| P/S ratio | 110.09 | N/A |
| P/B ratio | 1.17 | 4.00 |
Profitability
| Metric | ALLO | MNPR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -3566.68% | 0.00% |
| ROE | -37.94% | -13.64% |
| ROIC | -34.79% | -16.89% |
Growth (annualized)
| Metric | ALLO | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | N/A |
| Total return CAGR (5Y) | -42.72% | 27.38% |
Frequently asked
- How have ALLO and MNPR total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.